Skip to content
Screener

PP&E (Net) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$5.46B
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$10.01M+14.3%
Bausch + Lomb logo
Bausch + LombBLCO
$1.8B+7.1%
HRO
HarrowHROW
$3.13M-12.3%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$20.49M+544%
Schering-Plough logo
Schering-PloughSGP
$2.75M

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$1.92B-11.7%
Enterprise value$1.33B-28.4%
P/S36.9×-1.5×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 7:28 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-055256
Line itemMarch 31, 2026December 31, 2025
Inventory3,7373,564
Prepaid expenses and other current assets11,21210,855
Total current assets705,995782,129
Property and equipment, net18,42519,676
Restricted cash1,6141,614
Operating lease assets6,4954,638
Total assets$732,529$808,057
Liabilities and Stockholders’ Equity

Item 1. Financial Statements (unaudited)

FAQ

What is Ocular Therapeutix's PP&E (net)?
Ocular Therapeutix (OCUL) reported PP&E (net) of $18.43M in Q1 2026.
How has Ocular Therapeutix's PP&E (net) changed year-over-year?
Ocular Therapeutix's PP&E (net) increased by 70.9% year-over-year, from $10.78M to $18.43M.
What is the long-term trend for Ocular Therapeutix's PP&E (net)?
Over 5 years (2020 to 2025), Ocular Therapeutix's PP&E (net) has grown at a 19.4% compound annual growth rate (CAGR), from $8.1M to $19.68M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about Ocular Therapeutix's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude